IPI-549 is an oral, selective phosphoinositide-3-kinase gamma (PI3K-gamma) inhibitor, and the partners believe the combination will help overcome resistance to PD-1s seen in these patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback